-

Viz.ai Wins Four Comparably Awards for Best Place to Work

Healthcare technology leader recognized for its culture, diversity, career growth and outlook

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has received two additional Comparably Best Place to Work Awards for Best Company Culture and Best Company for Diversity in 2022. Earlier this year, the Company was also awarded Best Company Outlook and Best Company Career Growth, bringing its total to four Comparably awards.

“We are honored to receive these distinguished awards as they are a true testament to our people-centric business built on kindness and collaboration. Viz.ai is uniquely positioned to increase access to life-saving treatments through the power of artificial intelligence and our broad hospital network, so it’s important our employees feel encouraged and supported in all aspects of life,” said Chris Mansi, CEO at Viz.ai. “I would like to extend my deepest gratitude to those who participated in the Comparably ratings. Your feedback is imperative to the ongoing improvements of our workplace experience.”

Comparably recognizes exceptional companies with the Best Place to Work Awards based on anonymous employee ratings about their workplaces over a 12-month period. The final dataset was compiled from 15 million ratings across 70,000 large and small U.S. companies. Viz.ai’s Employee Net Promoter Score (eNPS) was 72, which is in the top 10 percent of 1,670 similarly-sized companies.

“Viz.ai has quickly become a leader in using artificial intelligence to expedite disease detection and care, but this wouldn’t be possible without the dedication of our passionate and hard-working team,” said Dawn Sprague, vice president of people at Viz.ai. “Building a workplace environment that nurtures each individual’s identity, goals, and career path ensures our employees come to work energized to create and deliver solutions that inform critical care decisions, helping improve patient lives.”

To learn about opportunities to join Viz.ai, please visit https://www.viz.ai/careers.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,200+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Contacts

Erich Sandoval
erich.sandoval@finnpartners.com
+1 917 497 2867

Viz.ai


Release Versions

Contacts

Erich Sandoval
erich.sandoval@finnpartners.com
+1 917 497 2867

Social Media Profiles
More News From Viz.ai

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom